Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Nature

Volumn 546, Issue 7659, 2017, Pages 498-503

  Kamerkar, Sushrut ^a   Lebleu, Valerie S ^a   Sugimoto, Hikaru ^a   Yang, Sujuan ^a   Ruivo, Carolina F ^b,c   Melo, Sonia A ^a,b,c   Lee, J Jack ^a   Kalluri, Raghu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; K RAS PROTEIN; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; NANOCARRIER; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; CD47 PROTEIN, MOUSE; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

BLOOD; CANCER; CELLS AND CELL COMPONENTS; EXPERIMENTAL STUDY; GENETIC ANALYSIS; MUTATION; RNA; RODENT;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CIRCULATION; CONTROLLED STUDY; EXOSOME; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MESENCHYME CELL; METASTASIS INHIBITION; MONOCYTE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHAGOCYTOSIS; PINOCYTOSIS; PRIORITY JOURNAL; RNAI THERAPEUTICS; ANIMAL; BLOOD; CYTOLOGY; DISEASE MODEL; FEMALE; GENE SILENCING; GENE THERAPY; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL RATE;

MUS;

ANIMALS; ANTIGENS, CD47; DISEASE MODELS, ANIMAL; EXOSOMES; FEMALE; GENE SILENCING; GENETIC THERAPY; LIPOSOMES; MICE; MONOCYTES; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PINOCYTOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, SMALL INTERFERING; SURVIVAL RATE;

EID: 85021081225     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22341     Document Type: Article

References (51)

1. Hidalgo, M. & Von Hoff, D. D. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin. Cancer Res. 18, 4249-4256 (2012).
2. Chang, D. K., Grimmond, S. M. & Biankin, A. V. Pancreatic cancer genomics. Curr. Opin. Genet. Dev. 24, 74-81 (2014).
3. Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639-653 (2012).
4. Collins, M. A. et al. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One 7, e49707 (2012).
5. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
6. Gysin, S., Salt, M., Young, A. & McCormick, F. Therapeutic strategies for targeting Ras proteins. Genes Cancer 2, 359-372 (2011).
7. Pecot, C. V. et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol. Cancer Ther. 13, 2876-2885 (2014).
8. Yuan, T. L. et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 4, 1182-1197 (2014).
9. Xue, W. et al. Small RNA combination therapy for lung cancer. Proc. Natl Acad. Sci. USA 111, E3553-E3561 (2014).
10. Réjiba, S., Wack, S., Aprahamian, M. & Hajri, A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci. 98, 1128-1136 (2007).
11. Zorde Khvalevsky, E. et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20723-20728 (2013).
12. van der Meel, R. et al. Extracellular vesicles as drug delivery systems: Lessons from the liposome field. J. Control Release 195, 72-85 (2014).
13. Kowal, J., Tkach, M. & Théry, C. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 29, 116-125 (2014).
14. Johnsen, K. B. et al. A comprehensive overview of exosomes as drug delivery vehicles-endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 1846, 75-87 (2014).
15. Vader, P., Mol, E. A., Pasterkamp, G. & Schiffelers, R. M. Extracellular vesicles for drug delivery. Adv. Drug Deliv. Rev. 106, 148-156 (2016).
16. Kaur, S. et al. CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells. Matrix Biol. 37, 49-59 (2014).
17. Kibria, G. et al. A rapid, automated surface protein profiling of single circulating exosomes in human blood. Sci. Rep. 6, 36502 (2016).
18. Brown, E. J. & Frazier, W. A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11, 130-135 (2001).
19. Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
20. Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRP pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225-232 (2012).
21. Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633-637 (2013).
22. Simões, S. et al. Cationic liposomes for gene delivery. Expert Opin. Drug Deliv. 2, 237-254 (2005).
23. Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRP ) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662-6667 (2012).
24. Nakase, I., Kobayashi, N. B., Takatani-Nakase, T. & Yoshida, T. Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes. Sci. Rep. 5, 10300 (2015).
25. Özdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734 (2014).
26. Ijichi, H. et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest. 121, 4106-4117 (2011).
27. Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80-93 (2014).
28. Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
29. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
30. Guerra, C. & Barbacid, M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol. Oncol. 7, 232-247 (2013).
31. Ying, H. et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 30, 355-385 (2016).
32. Gidekel Friedlander, S. Y. et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16, 379-389 (2009).
33. Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836-847 (2012).
34. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
35. Eser, S., Schnieke, A., Schneider, G. & Saur, D. Oncogenic KRAS signalling in pancreatic cancer. Br. J. Cancer 111, 817-822 (2014).
36. Singh, H., Longo, D. L. & Chabner, B. A. Improving prospects for targeting RAS. J. Clin. Oncol. 33, 3650-3659 (2015).
37. Zeitouni, D., Pylayeva-Gupta, Y., Der, C. J. & Bryant, K. L. KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers (Basel) 8, E45 (2016).
38. Golan, T. et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 6, 24560-24570 (2015).
39. Kordelas, L. et al. MSC-derived exosomes: a novel tool to treat therapyrefractory graft-versus-host disease. Leukemia 28, 970-973 (2014).
40. Clayton, A., Harris, C. L., Court, J., Mason, M. D. & Morgan, B. P. Antigen-presenting cell exosomes are protected from complementmediated lysis by expression of CD55 and CD59. Eur. J. Immunol. 33, 522-531 (2003).
41. Gomes-da-Silva, L. C. et al. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc. Chem. Res. 45, 1163-1171 (2012).
42. Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525-530 (2015).
43. Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177-182 (2015).
44. Melo, S. A. et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26, 707-721 (2014).
45. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341-345 (2011).
46. El-Andaloussi, S. et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protocols 7, 2112-2126 (2012).
47. Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. Chapter 3, Unit 3. 22 (2006).
48. Ma, J. B., Ye, K. & Patel, D. J. Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429, 318-322 (2004).
49. Du, Q., Thonberg, H., Wang, J., Wahlestedt, C. & Liang, Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33, 1671-1677 (2005).
50. Rachagani, S. et al. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br. J. Cancer 104, 1038-1048 (2011).
51. Poliseno, L. et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465, 1033-1038 (2010).